Comparative effectiveness research: The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness

Eleanor L. Olvey; Karen MacDonald; Ivo Abraham

doi:10.3233/PPL-2011-0340

Comparative effectiveness research: The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness

Eleanor L. Olvey, Karen MacDonald, Ivo Abraham

Pharmacy Practice and Science

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Recent health care legislation in the United States has turned considerable focus to comparative effectiveness research (CER) domestically, though it has been a topic of discussion internationally for many years. Without a fully comprehensive and consistent definition of CER developed, much uncertainty and confusion surrounds its utilization. In addition, contention exists regarding the incorporation of cost and economic considerations as a component of CER. This discussion includes various suggested definitions of CER, methodological considerations, legislation and utilization, and the role of cost-effectiveness evaluations in CER.

Original language	English (US)
Pages (from-to)	27-35
Number of pages	9
Journal	Pharmaceuticals Policy and Law
Volume	14
Issue number	1
DOIs	https://doi.org/10.3233/PPL-2011-0340
State	Published - Feb 20 2012

Keywords

Comparative effectiveness research (CER)
effectiveness
health technology assessment
outcomes
pharmacoeconomics

ASJC Scopus subject areas

Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Health Policy

Access to Document

10.3233/PPL-2011-0340

Fingerprint Dive into the research topics of 'Comparative effectiveness research: The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness'. Together they form a unique fingerprint.

Cite this

@article{70befe7f6ec348f8a2ad8d0aef6b9aa9,

title = "Comparative effectiveness research: The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness",

abstract = "Recent health care legislation in the United States has turned considerable focus to comparative effectiveness research (CER) domestically, though it has been a topic of discussion internationally for many years. Without a fully comprehensive and consistent definition of CER developed, much uncertainty and confusion surrounds its utilization. In addition, contention exists regarding the incorporation of cost and economic considerations as a component of CER. This discussion includes various suggested definitions of CER, methodological considerations, legislation and utilization, and the role of cost-effectiveness evaluations in CER.",

keywords = "Comparative effectiveness research (CER), effectiveness, health technology assessment, outcomes, pharmacoeconomics",

author = "Olvey, {Eleanor L.} and Karen MacDonald and Ivo Abraham",

year = "2012",

month = feb,

day = "20",

doi = "10.3233/PPL-2011-0340",

language = "English (US)",

volume = "14",

pages = "27--35",

journal = "Pharmaceuticals Policy and Law",

issn = "1389-2827",

publisher = "IOS Press",

number = "1",

}

TY - JOUR

T1 - Comparative effectiveness research

T2 - The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness

AU - Olvey, Eleanor L.

AU - MacDonald, Karen

AU - Abraham, Ivo

PY - 2012/2/20

Y1 - 2012/2/20

N2 - Recent health care legislation in the United States has turned considerable focus to comparative effectiveness research (CER) domestically, though it has been a topic of discussion internationally for many years. Without a fully comprehensive and consistent definition of CER developed, much uncertainty and confusion surrounds its utilization. In addition, contention exists regarding the incorporation of cost and economic considerations as a component of CER. This discussion includes various suggested definitions of CER, methodological considerations, legislation and utilization, and the role of cost-effectiveness evaluations in CER.

AB - Recent health care legislation in the United States has turned considerable focus to comparative effectiveness research (CER) domestically, though it has been a topic of discussion internationally for many years. Without a fully comprehensive and consistent definition of CER developed, much uncertainty and confusion surrounds its utilization. In addition, contention exists regarding the incorporation of cost and economic considerations as a component of CER. This discussion includes various suggested definitions of CER, methodological considerations, legislation and utilization, and the role of cost-effectiveness evaluations in CER.

KW - Comparative effectiveness research (CER)

KW - effectiveness

KW - health technology assessment

KW - outcomes

KW - pharmacoeconomics

UR - http://www.scopus.com/inward/record.url?scp=84856823973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856823973&partnerID=8YFLogxK

U2 - 10.3233/PPL-2011-0340

DO - 10.3233/PPL-2011-0340

M3 - Article

AN - SCOPUS:84856823973

VL - 14

SP - 27

EP - 35

JO - Pharmaceuticals Policy and Law

JF - Pharmaceuticals Policy and Law

SN - 1389-2827

IS - 1

ER -

Comparative effectiveness research: The translational science of comparing the what, how, when, in whom, by whom, and why of treatment effectiveness

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this